Immatics (NASDAQ:IMTX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.
Other analysts have also recently issued reports about the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immatics in a research note on Thursday, January 22nd. Jefferies Financial Group initiated coverage on Immatics in a research note on Monday, March 16th. They issued a "buy" rating and a $18.00 price objective on the stock. TD Cowen initiated coverage on Immatics in a research note on Tuesday. They issued a "buy" rating on the stock. Finally, Mizuho set a $25.00 price objective on Immatics in a research note on Thursday, February 19th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $19.00.
Read Our Latest Stock Analysis on IMTX
Immatics Stock Down 1.8%
Immatics stock opened at $10.79 on Friday. The firm has a market cap of $1.45 billion, a PE ratio of -5.86 and a beta of 1.31. Immatics has a 52-week low of $3.94 and a 52-week high of $12.41. The company's 50 day moving average is $10.29 and its two-hundred day moving average is $10.11.
Immatics (NASDAQ:IMTX - Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.14. The company had revenue of $23.18 million for the quarter, compared to analyst estimates of $12.18 million. Immatics had a negative net margin of 411.90% and a negative return on equity of 41.81%. On average, equities research analysts anticipate that Immatics will post -1.49 earnings per share for the current fiscal year.
Institutional Trading of Immatics
Several hedge funds have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd acquired a new stake in Immatics in the first quarter valued at $742,000. T. Rowe Price Investment Management Inc. raised its stake in Immatics by 10.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company's stock valued at $225,322,000 after buying an additional 2,075,987 shares in the last quarter. Virtus Investment Advisers LLC raised its stake in Immatics by 43.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company's stock valued at $278,000 after buying an additional 7,965 shares in the last quarter. SummitTX Capital L.P. raised its stake in Immatics by 117.7% in the fourth quarter. SummitTX Capital L.P. now owns 96,784 shares of the company's stock valued at $1,016,000 after buying an additional 52,318 shares in the last quarter. Finally, Tudor Investment Corp ET AL acquired a new stake in Immatics in the fourth quarter valued at $575,000. 64.41% of the stock is currently owned by institutional investors and hedge funds.
About Immatics
(
Get Free Report)
Immatics N.V. NASDAQ: IMTX is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient's immune system. Immatics' approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.
At the core of Immatics' technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
